Tocainide Pregnancy and Breastfeeding Warnings
Brand names: Tonocard
Tocainide Pregnancy Warnings
Tocainide has been assigned to pregnancy category C by the FDA. Animal studies using dosages 1 to 12 times that recommended in humans (on a per kg basis) failed to reveal evidence of teratogenicity. An increase in abortions, stillbirths and decreased offspring survival within the first week postpartum was noted. There are no controlled data in human pregnancy. Tocainide should be given during pregnancy only when benefit outweighs risk.
Tocainide Breastfeeding Warnings
There are no data on the excretion of tocainide into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See also
References for pregnancy information
- Product Information. Tonocard (tocainide). Merck & Co., Inc. 2002;PROD.
- Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1995;130:871-6.
References for breastfeeding information
- Product Information. Tonocard (tocainide). Merck & Co., Inc. 2002;PROD.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
